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(http://creativecommons.org/licenses/by-nc-nd/4.0/). http://dx.doi.org/10.10prevalence of DM and CAD is growing primarily due to
the rising prevalence of obesity. The rapidly changing life
style, especially in developing countries, plays major role
in the occurrence of these diseases.
Methods: We performed a literature review to summarize
and explore the relationship between CAD and DM with
a special focus on Arab countries in terms of risk factors
and prevalence. We suggest future directions to prevent
escalation in the incidence of DM and CAD in Arab
countries.
Conclusion: An important part of any preventive pro-
gram for CAD should include clear prevention strategies
for DM and other associated metabolic risk factors, such
as obesity. Preventive measures, such as physical exercise
in high-risk groups, at the population level should be
encouraged.
Keywords: Arab world; Coronary artery disease; Diabetes
mellitus; Obesity; Physical exercise
 2016 The Authors.
Production and hosting by Elsevier Ltd on behalf of Taibah
University. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Coronary artery disease (CAD) is a major cause of death
in Western countries, and it is becoming a major cause of
death in developing countries. This increasemay be due to the
rising prevalence of many CAD risk factors, such as diabetes,
which is one of the most important of these risk factors. The
prevalence of diabetes is increasing globally, and it has
reached pandemic levels in the Middle East and worldwide.1his is an open access article under the CC BY-NC-ND license
16/j.jtumed.2016.03.005
Table 1: The adjusted prevalence of diabetes in some Arab
counties in 2011 [adopted from Top 10 countries/territories for
prevalence (%) of people with diabetes (20e79 years), 2011
and 2030a].
Country The adjusted
prevalence (%)
Rank in top 10
countries for
prevalence
Kuwait 20.7 3
Qatar 19.8 5
KSA 19.6 6
Lebanon 19.6 7
Bahrain 19.5 8
United Arab of Emirates 18.8 10
a Adopted from The IDF Diabetes Atlas 201121.
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50% in many countries.2 The impact of tighter control of
diabetes on cardiovascular morbidity and mortality has been
controversial with conflicting results, which attracted special
attention in current diabetes management guidelines. The
measurement of this impact remains an active area of research.
Diabetes and atherosclerosis
Type 2 diabetes mellitus (DM) is a strong risk factor for
CAD, and experts consider DM an equivalent to established
CAD risk.3 Patients with diabetes have 2- to 4-fold greater
risk of developing CAD than non-diabetic patients.4,5
Diabetic patients exhibit an increased risk for develop-
ment of atherosclerotic CAD for many reasons, including
metabolic factors, like hyperglycaemia, dyslipidemia and
insulin resistance, which lead to endothelial cell, vascular
smooth muscle dysfunction,6,7 impaired platelet function
and abnormal coagulation.8 Diabetic patients tend to
exhibit other risk factors for CAD, like hypertension and
obesity. Patients with diabetes have lipid-rich atheroscle-
rotic plaques, which are more vulnerable to rupture than the
plaques seen in non-diabetic patients.9,10 Yoo et al. described
an overall increase in atherosclerotic burden and a 3.5-fold
higher risk of coronary stenosis that was independent of
other cardiovascular risk factors in diabetic patients.11
Inflammation plays an important role in atherosclerosis.
Inflammation activation in type 2 DM results from obesity
and insulin resistance, in which an acute phase reaction
occur, and a large number of inflammatory and pro-
inflammatory cytokines are released from adipose tissue.12
Endothelial dysfunction is generally present in diabetic
patients with CAD, as evidenced by high levels of
endothelin 1 and low levels of nitric oxide.13 Vascular
endothelial (VE)-cadherin was identified recently as an
updated marker of endothelial function that is well-
correlated with endothelin 1 in diabetic patients with CAD.14
Enhanced thrombus formation occurs in type 2 DM
because of increased platelet activity and blood coagula-
bility.15 Pathological alterations in fibrinogen and
plasminogen activation inhibitors are primarily relevant for
the short-term incidence of cardiovascular events in pa-
tients with type 2 DM.16
Notably, not all diabetic patients develop cardiovascular
disease despite the presence of the same risk factors. How-
ever, recent studies focused on biomarkers of CVD in dia-
betic patients, such as serum phospholipids and their role in
the progression of CVD. Beatriz Garcı´a-Fontana and col-
leagues recently found low serum levels of 4 phospholipids in
diabetic patients with CVD compared to diabetic patients
without CVD.17
A recent study found a new biomarker in type 2 DM
complicated with CAD that was significantly elevated and
positively correlated with the degree of CAD stenosis. This
new biomarker is called Osteonectin Secreted Protein Acidic
and Rich in Cysteine (SPARC). The mechanism by which
SPARC may cause CAD development requires further
research.18
Palazhy et al. evaluated oxidative stress in CAD patients
on statins in a cross-sectional study of 3 groups: Group 1,
healthy control; Group 2, patients with DM and CAD on
statins; Group 3, only diabetic patients. They found thatoxidative stress was higher in the CAD and DM group
despite statin therapy. These results highlighted the impor-
tance of oxidative stress.19
Diabetes as a risk factor for CAD
The prevalence of DM is increasing globally, and the
International Diabetes Federation (IDF) estimated that
there were 387 million people with DM in 2013, and this
incidence is expected to rise to 592 million by 2035. An
estimated 1 in 10 people have DM in the Middle East and
North Africa (MENA) region.20 Six of the top ten countries
with a high estimated prevalence of DMwere Arab countries
in the 2011 IDF global estimate: Kuwait, Lebanon, Qatar,
KSA, Bahrain and United Arab Emirates.21 Three of the
top 10 countries with a high estimated prevalence of DM
were Arab countries in the updated 2014 IDF estimate:
KSA, Kuwait and Qatar.20 (Table 1 and 2).
The overall prevalence of DM was 23.7%, (26.2% in
males & 21.5% in females) in a study of the prevalence of
diabetes in KSA,22 which was part of the Coronary Artery
Disease in Saudis Study (CADISS),23 and the impaired
fasting blood glucose was 14.1% for males and females
combined. A total of 27.9% of diabetics were unaware of
having diabetes,22 and 34% of diabetic patients were
hypertensive compared to 21.4% without DM
(P < 0.001).24 These factors further contribute to the risk
of CAD in the KSA population.
CADISS is a national community-based study that
examined 17,232 KSA subjects aged 30e70 years from
randomly selected households. The primary objective was to
estimate the prevalence of CAD and its risk factors in KSA.
The overall prevalence of CAD was 5.5% (6.6% in males,
4.4% in females).23
The prevalence of type 2 DM in KSA is expected to rise
because of the high prevalence of obesity. The overall prev-
alence of obesity was 35.6% in CADISS with a higher
prevalence in females (44%) compared to males (26.4%)
(P < 0.0001).25
Another important factor in the high prevalence of DM in
KSA is the high prevalence of physical inactivity, with an
overall prevalence of 96.1% (98.1% in females vs. 93.9% in
males) (P < 0.001).26
The prevalence of metabolic syndrome in KSA is also
very high (39.3%), and it is higher in females (42%)
Table 2: Top 10 countries/territories for prevalencea (%) of
people with diabetes (20e79 years), 2013 and 2035b.
2013 2035
Country/territory % Country/territory %
Tokelau 37.5 Tokelau 37.9
Federated States
of Micronesia
35.0 Federated States
of Micronesia
35.1
Marshall Islands 34.9 Marshall Islands 35
Kiribati 28.8 Kiribati 28.9
Cook Islands 25.7 Cook Islands 25.7
Vanuatu 24.0 KSA 24.5
KSA 24.0 Vanuatu 24.2
Nauru 23.3 Nauru 23.3
Kuwait 23.1 Kuwait 23.2
Qatar 22.9 Qatar 22.8
a Comparative prevalence.
b Adopted from The IDF Diabetes Atlas 201420.
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tients with metabolic syndrome was 67.8% compared to
15.7% in DM patients without metabolic syndrome.27
A recent cross-sectional community-based Indian study
published in January 2016 estimated the prevalence of CAD
and its risk factors and found that the age-adjusted preva-
lence of definite CAD was 3.5% in the entire study popula-
tion, 4.8% in males, and 2.6% in females. DM was found in
15% of the population, hypertension in 28%, smoking in
28%, and overweight or obesity in 59%.28
A recent study investigated the prevalence of CAD risk
factors in 1056 healthy adults in Brazil and found that the
prevalence of DMwas 11%, systemic hypertension was 40%,
family history of CAD was 50%, smoking was 23%, dysli-
pidemia was 43%, and overweight/obesity was 68%.29
Diabetes in CAD patients
Several studies in the Arabian Gulf region had limitations
because a large proportion of expatriates were included in
the population. This inclusion was reflected in the results that
revealed a similar prevalence in their country of origin.
Therefore, we excluded many of these studies from the cur-
rent review.
The World Health Organization (WHO) initiated a cross-
sectional study, the Prevention of Recurrences ofMyocardial
Infarction and Stroke (WHO-PREMISE), of 10,000 patients
in 10 countries, primarily the Middle East, which exhibits
coronary heart disease in approximately 85% of the popu-
lation and cerebrovascular disease (CVD) in approximately
15%. The working group found a high prevalence of some
risk factors, and DM was found in approximately one third
of the patients (31.5%).30
National data from Lebanon are scarce. The Lebanese
Interventional Registry provided data of the cardiovascular
risk factors of patients who presented for coronary angiog-
raphy. The risk factors included DM (29%), hypertension
(60%), smoking (50%), and dyslipidemia (29%).31
The INTERHEART study is a case-control study of
modifiable risk factors in acute myocardial infarction pa-
tients. The investigators studied 15,152 patients and 14,820
controls, which included more than 1500 patients and 1700controls from the Middle East. Subgroup analysis of the
Middle East group revealed a diabetes prevalence of
approximately 15%, hypertension was present in approxi-
mately 9%, and current smokers included approximately
45% of cases. Dyslipidemia and abdominal obesity were
present in 70% and 25% of cases, respectively.32
The Gulf Registry of Acute Coronary Events (Gulf
RACE) is the first multi-national acute coronary syndrome
registry in the Middle East. These investigators studied pa-
tients with in the United Arab Emirates, Kuwait, Bahrain,
Oman, Qatar and Yemen. A total of 1484 ACS patients were
recruited. Myocardial infarction formed the majority of
cases (approximately 69%), and DM prevalence was rela-
tively high (38%). Hypertension was present in 46% of the
study population, hyperlipidaemia in 31%, and smoking in
45%.33
The Second Gulf Registry of Acute Coronary Events
(Gulf RACE 2) is a registry studying the effects of DM and
new-onset hyperglycaemia on cardiovascular outcomes in
ACS patients from Arabian Gulf countries. More than 7000
patients were recruited from 6 Arabian Gulf countries: KSA,
Bahrain, Qatar, Oman, United Arab Emirates, and Yemen.
The prevalence of DM was high; 49.2% of the study patients
had been diagnosed previously with DM (23% on insulin,
and 76% treated with oral anti-diabetic agents and/or diet
control). New-onset hyperglycaemia was estimated at 8.8%.2
The DM prevalence reported in Gulf RACE 2 was very
high compared to the Western data in the Global Registry of
Acute Coronary Events (GRACE) registry (approximately
24%)34 and the Asian data found in treatment and outcomes
of ACS in an Indian registry (about 30%).35
Hersi et al. examined the gender difference between pa-
tients with ACS from 17 participating centres in KSA. More
than 5000 patients were recruited, and the prevalence of DM
in the entire study population was even higher at 58%, 73%
in the female subgroup, and 41% in the male subgroup.36
Mobeirek and co-workers found a relatively high preva-
lence of risk factors in the SPACE registry (the KSA Patients
Admitted with acute Coronary syndromes registry) in KSA:
DM (57%), overweight or obesity (72%), hypertension
(56.6%), dyslipidemia (42%), and smoking (32.4%).37
A total of 16,736 patients with acute coronary syndrome
were studied in a 20-year registry (1991 to the end of 2010)
from Hamad Medical Corporation (HMC) in Qatar. This
centre provides medical services to different ethnicities in the
area, and the results should be interpreted carefully. The
prevalence rates of DM were 65.7% and 37.4% in females
and males, respectively, and hypertension prevalence was
estimated as 68.1% in females and 36.5% in males.38
Abdelmoneim and colleagues published the results of
their cross-sectional observational study of the demographic
of ACS in Egypt in 2014. They studied 795 ACS patients
divided into 2 groups: group 1 (270 patients), ST segment
Elevation Myocardial Infarction (STEMI) and group 2 (525
patients), Unstable Angina/Non-ST Segment Elevation
Myocardial Infarction (UA/NSTEMI). The prevalence of
DM in these groups was 34% and 45%, respectively. Other
reported risk factors in these groups were hypertension (33%
and 59%, respectively), dyslipidemia (29% and 39%,
respectively), smoking (51% and 38%, respectively), family
history (16% and 7%, respectively), and male gender (72%
and 64%, respectively).39
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STEMI and classified patients into 2 groups according to
waist circumference. The prevalence of diabetes was (53/142)
37.3% in the entire study population. The prevalence of other
risk factors was hypertension 41.5%, current smoking 49.3%,
and family history of coronary artery disease 16.2%.40
Jain et al. (2015) investigated the risk factors for post-
myocardial infarctions and assessed coronary artery anat-
omy using coronary angiography. They found that the
prevalence of DM was 28.2%, hypertension was 31.4%,
dyslipidemia was 37.5%, and current smoker was 44.9%.41
Screening of diabetic patients for CAD
The 2015 American Diabetes Association (ADA) rec-
ommendations suggest that diabetic patients who are can-
didates for advanced investigations that may include
coronary angiography are patients with cardiac symptoms
(either typical or atypical) or patients with abnormal resting
electrocardiogram (ECG). Routine screening of asymptom-
atic patients is not recommended42 because high-risk diabetic
patients for CAD should receive optimal medical therapy
(OMT) to reduce the incidence of cardiovascular events, even
if they are asymptomatic. A large body of evidence confirms
that OMT provides similar benefits as percutaneous coro-
nary intervention (PCI) in stable CAD. This evidence came
from 2 landmark trials: the first trial, the Clinical Outcomes
Utilizing Revascularization and Aggressive Drug Evaluation
(COURAGE) trial43; and the second trial, the “Bypass
Angioplasty Revascularization Investigation 2 Diabetes”
(BARI 2D) Trial.44
Other studies also demonstrate that the coronary artery
calcium score (CACS) provides refined risk stratification for
high-risk patients,45 but coronary computed tomography
angiography (CCTA) provides a more detailed assessment
of subclinical CAD and had a better prognostic value than
CACS.46
The Detection of Ischemia in Asymptomatic Diabetics
(DIAD) study assessed cardiac autonomic neuropathy in
1119 asymptomatic type 2 DM patients using autonomic
heart rate, blood pressure, and heart rate variability. Cardiac
autonomic neuropathy predicted adverse cardiac events in
8.4% of the studied population who developed symptomatic
cardiac disease during the 5 years of follow-up.47
The COURAGE trial examined 2287 patients with stable
CAD with objective evidence of ischaemia who were rand-
omised to PCI with OMT versus OMT alone. The primary
outcome endpoint was a composite of death from any cause
and non-fatal myocardial infarction. There was no signifi-
cant difference in the primary outcome at the mean follow-
up of 4.6 years. Therefore, the addition of early PCI to
OMT did not reduce the long-term risk of death or
myocardial infarction (MI) in COURAGE patients regard-
less of diabetes status.48 The BARI-2D trial examined the
coronary revascularization using PCI or Coronary Artery
Bypass Grafting (CABG) versus intensive medical therapy in
patients with type 2 diabetes. The research group found no
significant difference in the all-cause mortality or the com-
posite endpoints of death, MI or stroke (BARI-2D trial).44
A total of 1123 diabetic patients were recruited in the
DIAD study, and 522 patients were randomised foradenosine-stress myocardial perfusion imaging screening. A
total of 358 patients underwent repeat adenosine-stress
myocardial perfusion imaging 3 years after the first evalua-
tion. Fifty-six of the 71 patients with abnormal studies dur-
ing the initial evaluation (79%) had resolution of ischaemia
on the myocardial perfusion scan after 3 years. Fifteen (21%)
patients had abnormal studies at follow up. There were more
patients using aspirin, statins, and angiotensin-converting
enzyme inhibitors (ACEIs) at the 3-year follow up than the
initial evaluations. This increase supports the evidence that
silent myocardial ischaemia may resolve over time with
OMT. This result undermines the strategy of routine
aggressive screening of asymptomatic diabetic patients and
emphasises the importance of the use of evidence-based
OMT for high-risk patients.49 The benefits of newer non-
invasive CAD screenings, such as computed tomography
angiography, are not well established, and their use as a
routine screening tool in asymptomatic diabetic patients may
lead to undue radiation exposure and interventional
procedures.42
Management of CAD in diabetes
Reduction of diabetic macrovascular disease
Diabetics are at increased risk of developing cardiovas-
cular disease and total death compared to non-diabetics.50,51
The United Kingdom Prospective Diabetes Study
(UKPDS) is a landmark study of modifiable risk factors in
more than 3000 type 2 diabetics: increased levels of low-
density lipoprotein (LDL) cholesterol, low levels of high-
density lipoprotein (HDL) cholesterol, hypertension, and
smoking. The median follow-up period was approximately 8
years. Coronary artery disease was significantly associated
with these risk factors.52
Reduction of macrovascular complications in type 2 DM
was confirmed using good blood pressure control, but tight
glycaemic control was not conclusively demonstrated as
beneficial.53 Intensive glycaemic control in type 1 DM
demonstrated long-term benefits on macrovascular compli-
cations and mortality in the Diabetes Control and Compli-
cations Trial/Epidemiology of Diabetes Interventions and
Complications (DCCT/EDIC) study.54
A meta-analysis on cardiovascular risk reduction found
that smoking cessation was the most important intervention
in reducing mortality compared to other interventions. This
study concluded that smoking cessation may prolong life in a
45-year-old male diabetic patient for a mean of 3 years and a
mean of 4 years in non-diabetic male patients.55
The Veteran Affairs Diabetes Trial (VADT) demon-
strated in its extended follow-up arm that intensive glycaemic
control group had a significant lower risk of primary out-
comes compared to the standard therapy group. The abso-
lute risk reduction was 8.6 major cardiovascular events per
1000 person-years. However, there was no reduction in car-
diovascular mortality or total mortality.56 These researchers
found a 17% relative risk reduction in the rate of
cardiovascular events in the intensive medical therapy
group. The results of the follow up study of the Action to
Control Cardiovascular Risk in Diabetes blood pressure
trial (the ACCORD trial) exhibited a similar result with
Coronary artery disease and diabetes334fewer non-fatal cardiovascular events, and the conclusion
from the extended follow-up arm was not very different from
the original trial, especially that the overall mortality
remained higher in the intensive glycaemic control group.57
Use of anti-platelet drugs in DM
The recent recommendations of American Diabetes As-
sociation (ADA) published in 2015 suggest aspirin (75e
162 mg) for secondary prevention of CAD and primary
prevention in patients with high cardiovascular risk, with an
estimated 10-year risk of more than 10%. This group in-
cludes males older than 50 years or females older than 60
years with one or more of the following risk factors: hyper-
tension, dyslipidemia, family history of cardiovascular dis-
ease, smoking, and albuminuria.42 Clopidogrel is indicated
for patients with cardiovascular disease and documented
aspirin allergy.58
Blood pressure control
The UKPDS confirmed in early 1998 that tight treatment
of hypertension in diabetic patients was associated with
better outcomes than less tight control. The mean achieved
BP was 144/82 mmHg in the tight control group versus 154/
87 mmHg in the less tight control group. The tight BP con-
trol arm exhibited a risk reduction of 24% in any related DM
endpoints, 32% in diabetes-related death, 44% in strokes,
and 37% in microvascular complications.59
The Action in Diabetes and Vascular disease: PreterAx
and DiamicroN MR Controlled Evaluation (ADVANCE)
trial demonstrated that major macrovascular and micro-
vascular events were reduced significantly in the active BP
intervention arm (a single pill, fixed-dose combination of
perindopril and indapamide), and this result was associated
with reductions in all-cause mortality and cardiovascular
mortality. A blood pressure of 136/73 mmHg was the level
attained in the active treatment arm.60 Reductions in all-
cause mortality and cardiovascular mortality was attenu-
ated in the 6-year follow-up of the ADVANCE-BP study,
but it continued to be significant.61
Several of the major guidelines for the management of
hypertension, including the Eighth Joint National Commit-
tee (JNC-8)62 and the European Societies of Hypertension
and Cardiology (ESH/ESC),63 suggested that the goal of
blood pressure control in diabetics should be less than 140/
90 mmHg. Previous guidelines recommended blood
pressure control to less than 130/80 mmHg.
The Action to Control Cardiovascular Risk in Diabetes
blood pressure trial Blood Pressure (ACCORD-BP) arm
recruited a total of 4733 patients who were randomly
assigned to intensive (systolic BP goal below 120 mmHg)
versus standard (systolic BP goal below 140 mmHg) blood
pressure control and followed up to 4.7 years. There was a
statistically significant reduction in the annual incidence of
stroke (total stroke and non-fatal stroke) in the intensive BP
control group, but there was no significant difference be-
tween the two groups in the primary composite endpoint of
non-fatal MI, non-fatal stroke or death from cardiovascular
causes. There was also no difference in all-cause mortality.
Serious side effects were reported in the intensive BP arm,such as a significant rise in serum creatinine of more than
1.5 mg/dl, hyperkalemia, hypotension, and syncope.64
A meta-analysis of ACCORD-BP, Appropriate Blood
Pressure Control in NIDDM Trial (ABCD), and The Hy-
pertension Optimal Treatment (HOT) trials reported that
intensive BP control in diabetic patients significantly reduced
the risk of stroke but failed to reduce the incidence of
myocardial infarction or total mortality.65
The JNC-8 in white adult (>18 years) patients suggested
that the initial antihypertensive regimen should include
thiazide diuretic, a calcium channel blocker (CCB), and
ACEI or angiotensin receptor blockers (ARBs). However,
the initial treatment in black adult (>18 years) patients
should include a thiazide diuretic or CCB. ACEI or ARB
should be included in the treatment of patients with chronic
kidney disease (CKD), regardless of diabetes status or
race62.
The Heart Outcomes Prevention Evaluation (HOPE) trial
investigated a total of 9297 patients with diabetes or evidence
of vascular disease (high-risk group) and randomised pa-
tients to ramipril or placebo control groups. Ramipril
significantly reduced the primary endpoint of myocardial
infarction, stroke or death from cardiovascular disease.66
Statins in DM
A meta-analysis of 14 randomised trials of statins
involved 18,686 diabetic patients who were followed up for
4.3 years. There was a 9% proportional reduction in all-
cause mortality and 13% reduction in vascular mortality
for each one mmol/l reduction of LDL-cholesterol.67
The ADA standard of medical care of diabetes in 2015
states that diabetic patients aged >40 years should receive
moderate intensity statins with life-style modifications, but
high-dose statins are indicated in patients with cardiovas-
cular diseases or other risk factors.42 Cannon and colleagues
investigated an intensive lipid-lowering regimen (atorvasta-
tin 80 mg/day) versus a moderate regimen (pravastatin
40 mg/day) in 4162 ACS patients. The high-intensity regimen
of atorvastatin provided significantly greater protection
against death and cardiovascular events compared to the
moderate regimen of pravastatin after a 2-year follow up.68
There is scarce data on the use of statins in diabetics under
the age of 40 years, and the current recommendations do
not indicate statin use for diabetic patients below 40 years
of age without overt cardiovascular disease or other risk
factors.42
Coronary revascularization in diabetics
Selection of the optimal method of coronary revascular-
isation for diabetic patients often requires a multidisciplinary
team meeting (i.e., a heart team). The Bypass Angioplasty
Revascularization Investigation 2 Diabetes (BARI 2D) trial
was a landmark trial that addressed the treatment of diabetic
patients with stable CAD. A total of 2368 patients with type
2 DM and stable CAD were enrolled and randomised to a
revascularization, coronary artery bypass graft (CABG) or
PCI group, according to individual physician’s preference,
plus intensive medical therapy (IMT) versus IMT alone. The
primary endpoints were the rate of death and the composite
M.M. Al-Nozha et al. 335cardiovascular events of death, MI or stroke. There was no
significant difference in the primary endpoints at the 5-year
follow-up. The cardiovascular events were significantly
lower in the CABG subgroup compared to the medical
treatment group, but mortality was not significant. There
was no significant difference in the risk of death and the
cardiovascular events between the PCI group plus IMT and
IMT alone.44
Diabetic patients are at an increased risk of progressive
coronary artery disease and coronary artery re-stenosis after
stent implantation. The predictors of coronary artery re-
stenosis are small vessel coronary artery, long lesion, and
lower body mass index.69,70
Drug-eluting stents (DES) are used preferentially used
over bare metal stents (BMS) in diabetic patients because
DES significantly reduce the incidence of re-stenosis and
target vessel revascularisation (TVR). Bangalore and col-
leagues published a meta-analysis of 42 trials with more than
22,000 patient-years of follow up and found that DES
significantly reduced the TVR compared to BMS (37e69%,
respectively). There was no increased risk of any safety
outcomes in the DES group, such as death, MI, or stent
thrombosis.71
The recent 5-year follow-up of (TAXUS Drug-Eluting
Stent Versus Coronary Artery Bypass Surgery for the
Treatment of Narrowed Arteries) SYNTAX trial investi-
gated the cause of death following PCI versus CABG in
complex CAD. Most death after PCI was due to a cardio-
vascular cause (67%), and myocardial infarction death
accounted for approximately 29%. Post-CABG deaths
included 49% due to cardiovascular cause. The cumulative
incidence rates of all-cause death were not significantly
different between CABG and PCI, but cardiovascular and
cardiac deaths were significantly higher in PCI group. A
difference between PCI and CABG in MI mortality was
found in diabetic patients, three-vessel CAD, and high
SYNTAX score. It was concluded that treatment with PCI
versus CABG was an independent predictor of cardiac death
in patients with complex CAD (hazard ratio: 1.55; 95%
confidence interval: 1.09 to 2.33; P ¼ 0.045).72Anti-diabetic agents and the risk of cardiovascular events
The hypothesis linking anti-diabetic agents with cardio-
vascular disease is not new. The 2007 meta-analysis that
linked rosiglitazone to increased cardiovascular risk and the
possibility of increasing cardiac events further added to this
concern.73 The decision of the Food and Drug
Administration (FDA) in the United States (U.S.) to
restrict the use of rosiglitazone because of this postulated
link resulted from this study. The chairman of the same
committee from the U.S. FDA wrote a perspective paper in
the New England Journal of Medicine (NEJM) to explain
the process of the FDA decision and announcement, and he
clarified his personal opinion about this decision, which
further added to this debate and controversy.74 The FDA
subsequently modified these restrictions in 2013 after their
re-evaluation of the results of the Rosiglitazone Evaluated
for CardiovascularOutcomes and Regulation of Glycemia in
Diabetes (RECORD) trial, which concluded that these trends
were not statistically significant, and the re-evaluationconfirmed the initial results of the original study.75 The
FDA recently eliminated the Risk Evaluation and
Mitigation Strategy (REMS) for rosiglitazone and
rosiglitazone-containing hypoglycaemic agents in 2015 and
stated “The REMS is no longer necessary to ensure that the
benefits of rosiglitazone medicines outweigh their risks”.76
Many concerns were raised about other agents and classes
intended to treat hyperglycaemia following the rosiglitazone
story. These concerns triggered a series of trials on newer
classes and agents and changed the process of approving
new anti-diabetic agents, at least by the U.S. FDA.Conclusion and recommendations
Diabetes is a very important major risk factor for CAD,
and it is becoming a global health problem with increasing
prevalence in a pandemic form. Many Arab countries,
especially the Arabian Gulf region, are at the top of the in-
ternational prevalence list. However, many Arab countries
do not possess updated prevalence data from the community
or maintain a registry of DM, CAD or other DM compli-
cations. Therefore, there is a great need to collect these data
in all Arab countries.
There is an urgent need for interventions at the population
level and in high-risk groups to reduce the incidence of DM
by promoting physical activity and controlling the obesity
epidemic. The prevalence of CADwill continue to rise in these
countries if no action is taken to control DM and other risk
factors for CAD, like hypertension and dyslipidemia.
International agencies, such as the WHO, IDF, ADA,
European Association for the Study of Diabetes (EASD),
American College of Cardiology (ACC) and the European
Society of Cardiology (ESC), should play an active role to
assist Arab countries to establish basic data and registries
and the promotion of health interventional programs to ul-
timately control the rising incidence of DM and CAD.
All efforts, governmental and non-governmental,
including all health organisations and scientific societies,
should come together locally in each country to combat this
epidemic of DM and CAD instead of individual scattered
efforts. We need uniformed programs at the national level to
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